Waldenström’s Macroglobulinemia
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to bett...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Cham :
Springer International Publishing : Imprint: Springer,
2017.
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Preface: Tribute to J Waldenström
- Part I: Tumor Cells and microenvironment
- Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
- Waldenström’s Macroglobulinemia Immunophenotype
- Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis
- Cytogenetics in Waldenstr<öm Macroglobulinemia (WM)
- Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia
- Molecular Pathways in Growth and Survival: Epigenomics
- The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia
- Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment
- Part II: Epidemiology and Genetic Predisposition
- Epidemiology of Waldenström Macroglobulinemia
- Genetic Predisposition to Waldenström Macroglobulinemia
- Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
- Part III: Clinical Features
- Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia
- Neuropathy in Waldenström’s Macroglobulinaemia
- IgM Amyloidosis
- The Bing-Neel Syndrome
- Unusual Manifestations of IgM Monoclonal Gammopathies
- Part IV: Laboratory Investigations
- Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
- Part V: Response
- Response Assessment in Waldenström’s Macroglobulinaemia
- Part VI: Prognostic Factors
- Risk Stratification in Waldenström Macroglobulinemia
- Part VII: Treatment Options and Recommendations
- Indications for Treatment of Waldenström’s Macroglobulinemia
- Immunotherapy in Waldenström’s Macroglobulinemia
- Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia
- Signal Inhibitors in Waldenström’s Macroglobulinemia
- High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia
- Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
- Treatment Recommendations in Waldenström Macroglobulinemia.
